Skip to main
COLL
COLL logo

Collegium Pharmaceutical (COLL) Stock Forecast & Price Target

Collegium Pharmaceutical (COLL) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 75%
Buy 0%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Collegium Pharmaceutical Inc. has demonstrated strong financial growth, with Jornay revenue increasing by 28.2% sequentially and achieving $42 million in revenue, surpassing expectations and representing a 19% year-over-year growth. The company has also seen substantial growth in total prescriptions for Jornay, reaching 192,000, which is a 20% increase from the previous year, contributing to a market share rise in the branded long-acting methylphenidate segment to 23.4%. Furthermore, Collegium raised its 2025 revenue guidance parameters, now expecting between $745 million and $760 million, which reflects optimistic projections for continued expansion within both pediatric and adult segments of its product lineup.

Bears say

Collegium Pharmaceutical Inc is currently facing significant financial challenges that contribute to a negative outlook for its stock. Despite achieving an operating cash flow of $78.4 million for the quarter, there are persistent risks, including declining prescription volumes for key products such as Xtampza ER and Belbuca, coupled with the potential threat of generic competition that could adversely impact revenue streams. Additionally, management's plan to decrease net leverage below 1.0x by year-end 2025 is overshadowed by concerns regarding inadequate supply from third parties, as well as unfavorable reimbursement and pricing dynamics that may inhibit profitability and product commercialization.

Collegium Pharmaceutical (COLL) has been analyzed by 4 analysts, with a consensus rating of Buy. 75% of analysts recommend a Strong Buy, 0% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Collegium Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Collegium Pharmaceutical (COLL) Forecast

Analysts have given Collegium Pharmaceutical (COLL) a Buy based on their latest research and market trends.

According to 4 analysts, Collegium Pharmaceutical (COLL) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Collegium Pharmaceutical (COLL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.